Reported positive FDA Type 2a meeting supporting ABP-450’s comparative analytical strategy under the 351(k) regulatory pathway -- Strengthened ...
Company continues to execute its analytical program and plans to request a BPD Type 2b meeting with the FDA in 2026 to discuss next steps in the development of ABP-450 as a biosimilar to BOTOX® During ...
AEON Biopharma, Inc. announced in its press release that it is advancing its biosimilar development program for ABP-450, a botulinum toxin complex, by initiating analytical studies to prepare for a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results